• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

    11/14/24 5:05:19 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LRMR alert in real time by email
    SC 13G/A 1 ef20038680_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*


    Larimar Therapeutics, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    517125100
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

    ☒
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    NAMES OF REPORTING PERSONS
     
     
    Blue Owl Capital Holdings LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    4,166,829
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    4,166,829
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,166,829
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.53%(1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Calculated based on 63,806,628 shares of Common Stock outstanding as of October 28, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on October 30, 2024.


    Item 1(a).
    Name of Issuer

    Larimar Therapeutics, Inc. (the “Issuer”)

    Item 1(b).
    Address of the Issuer’s Principal Executive Offices

    Three Bala Plaza East. Suite 506,
    Bala Cynwyd, PA, 19004

    Item 2(a).
    Names of Persons Filing

    This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the “Reporting Person.”

    Item 2(b).
    Address of the Principal Business Office, or if none, Residence

    399 Park Avenue
    New York, NY 10022

    Item 2(c).
    Citizenship

    See response to Item 4 on the cover page.

    Item 2(d).
    Title of Class of Securities

    Common Stock, par value $0.001 per share

    Item 2(e).
    CUSIP Number

    517125100

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a (n):

    (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)

    Item 4.
    Ownership


    (a)
    Amount beneficially owned:
    See response to Item 9 on the cover page.


    (b)
    Percent of Class:
    See response to Item 11 on the cover page.


    (c)
    Number of shares as to which the Reporting Person has:


    (i)
    Sole power to vote or to direct the vote:
    See response to Item 5 on the cover page.


    (ii)
    Shared power to vote or to direct the vote:
    See response to Item 6 on the cover page.


    (iii)
    Sole power to dispose or to direct the disposition of:
    See response to Item 7 on the cover page.


    (iv)
    Shared power to dispose or to direct the disposition of:
    See response to Item 8 on the cover page.

    The filing of this Statement shall not be construed as an admission that the Reporting Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement.

    Item 5.
    Ownership of Five Percent or Less of a Class

    Not Applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not Applicable.

    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group

    Not Applicable.

    Item 10.
    Certification

    By signing below I certify that / the Reporting Person certifies that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024
     
     
    BLUE OWL CAPITAL HOLDINGS LP
       
     
    By:
    /s/ Karen Hager
       
    Name:
    Karen Hager
       
    Title:
    Chief Compliance Officer



    Get the next $LRMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LRMR

    DatePrice TargetRatingAnalyst
    1/29/2025$18.00Buy
    Truist
    10/16/2024$26.00Outperform
    Oppenheimer
    10/3/2024$22.00Outperform
    Wedbush
    10/2/2024$15.00Buy
    H.C. Wainwright
    9/4/2024$16.00Outperform
    Robert W. Baird
    4/3/2024$25.00Outperform
    Leerink Partners
    11/17/2023$4.50Neutral → Buy
    Citigroup
    10/19/2022$12.00Buy
    Guggenheim
    More analyst ratings

    $LRMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Larimar Therapeutics Reports First Quarter 2025 Financial Results

      FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025 Strong balance sheet of $157.5 million cash, cash equivalents and marketable securities as of March 31, 2025, with projected cash runway into second quarter of 2026 BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE

      4/30/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approvalFDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and skeletal muscleLarimar is continuing discussions with FDA on the adequacy of the safety data set to support BLA submission BLA seeking accelerated approval targeted for submission by year-end 2025FDA

      3/24/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

      BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025. Details on the presentation can be found below. Date: Monday, March 10, 2025Time: 3:40 – 4:10 PM ESTWebcast Link: https://wsw.com/webcast/leerink38/lrmr/2247553 Following the conclusion of the presentation, a replay will be available for 30 days on the "Events an

      3/3/25 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hamilton Thomas Edward bought $499,998 worth of shares (57,208 units at $8.74), increasing direct ownership by 11% to 564,798 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/31/24 4:56:58 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flynn James E bought $37,499,993 worth of shares (4,290,617 units at $8.74) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/16/24 2:37:50 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas Frank E bought $22,000 worth of shares (2,000 units at $11.00) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/15/24 4:21:16 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 5:05:19 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 11:41:09 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 9:16:35 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Financials

    Live finance-specific insights

    See more
    • Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

      Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) studyTissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90Tissue FXN levels increased and were maintained over time, with mean levels increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90Early trends towards improvement in clinical outcomes were observed at Day 90, supporting the potential that nomlabofusp administration may result in a clinical benefit across a broad spectrum of patient

      12/16/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

      Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse eventsDose dependent increases in frataxin levels were observed in skin and buccal cells Open Label Extension (OLE) study initiated in January 2024 to dose 25 mg daily of nomlabofusp with dosing anticipated to be starting later this quarter; Initial data expected in Q4 2024Initiated discussions with the FDA on use of tissue frataxin levels as a novel surrogate endpoint to support a potential Biologics License Application ("BLA") submission for accelerated approval targeted for 2H 2025 Company management to host webcast and conference call today a

      2/12/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

      Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024Company management hosting a webcast and conference call today at 8:00 a.m. ET BALA CYNWYD, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601 i

      7/25/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Larimar Therapeutics with a new price target

      Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00

      1/29/25 7:39:50 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Larimar Therapeutics with a new price target

      Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00

      10/16/24 7:29:15 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Larimar Therapeutics with a new price target

      Wedbush initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $22.00

      10/3/24 7:34:56 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    SEC Filings

    See more
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      5/5/25 6:33:44 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Larimar Therapeutics Inc.

      10-Q - Larimar Therapeutics, Inc. (0001374690) (Filer)

      4/30/25 5:06:58 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      4/30/25 7:01:42 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Development Officer Shankar Gopi was granted 23,306 shares, increasing direct ownership by 85% to 50,806 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      1/24/25 4:16:59 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Clayton Russell was granted 23,306 shares, increasing direct ownership by 104% to 45,806 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      1/24/25 4:16:21 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Ben-Maimon Carole was granted 91,000 shares, increasing direct ownership by 31% to 387,208 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      1/24/25 4:15:42 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

      BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy. "Dr. Sherman is a pharmaceutical industry veteran who brings decades of leadership experience in global regulatory and clinical strategy to our Board of Directors.

      10/3/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

      Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Lari

      8/10/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

      BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell "Rusty" Clayton, DO, as Chief Medical Officer ("CMO"), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. "We are delighted to welcome Dr. Clayton in his new role as CMO as we further expand our clinical development of CTI-1601. Rusty has been one of our closest advisors for the last 5 years, has attended every meeting between Larimar and the FDA, in

      7/17/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care